The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Protein concentration is above or equal to 0.05 mg/ml.
Best use within three months from the date of receipt of this protein.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped on dry ice. Upon delivery aliquot and store at -80ºC. Avoid freeze / thaw cycles.
pH: 8.00 Constituents: 0.3% Glutathione, 0.79% Tris HCl
Class E basic helix-loop-helix protein 37
N myc proto oncogene protein
N-myc proto-oncogene protein
Neuroblastoma derived v myc avian myelocytomatosis viral related oncogene
Neuroblastoma MYC oncogene
NMYC proto oncogene protein
V myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog
v myc avian myelocytomatosis viral related oncogene neuroblastoma derived
v myc myelocytomatosis viral related oncogene neuroblastoma derived
May function as a transcription factor.
Involvement in disease
Note=Amplification of the N-MYC gene is associated with a variety of human tumors, most frequently neuroblastoma, where the level of amplification appears to increase as the tumor progresses. Defects in MYCN are the cause of microcephaly-oculo-digito-esophageal-duodenal syndrome (MODED) [MIM:164280]; also known as oculodigitoesophagoduodenal syndrome (ODED). Microcephaly-oculo-digito-esophageal-duodenal syndrome is characterized by variable combinations of esophageal and duodenal atresias, microcephaly, learning disability and limb malformations. Cardiac and renal malformations, vertebral anomalies, and deafness have also been described. Defects in MYCN are the cause of microcephaly and digital abnormalities with normal intelligence (MCPHDANI) [MIM:602585].